Empowered Funds LLC Acquires New Shares in Omnicell, Inc. $OMCL

Empowered Funds LLC acquired a new position in Omnicell, Inc. (NASDAQ:OMCL) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 153,338 shares of the company’s stock, valued at approximately $6,367,000.

Other large investors also recently bought and sold shares of the company. Jefferies Financial Group Inc. purchased a new position in Omnicell in the 2nd quarter worth about $1,524,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Omnicell during the 2nd quarter valued at about $2,253,000. Corient Private Wealth LP purchased a new stake in shares of Omnicell during the 2nd quarter valued at about $2,608,000. Odyssean LLC bought a new stake in shares of Omnicell in the second quarter worth approximately $2,235,000. Finally, Man Group plc bought a new stake in shares of Omnicell in the second quarter worth approximately $3,170,000. 97.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

OMCL has been the topic of a number of research analyst reports. Zacks Research downgraded shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Piper Sandler reiterated an “overweight” rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Finally, Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Price Performance

NASDAQ OMCL opened at $33.08 on Monday. Omnicell, Inc. has a 52 week low of $29.06 and a 52 week high of $55.00. The firm has a market capitalization of $1.50 billion, a P/E ratio of 39.38, a PEG ratio of 0.83 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $39.80 and a 200-day moving average price of $39.35.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. The firm had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The business’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 1.41 earnings per share for the current year.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.